ENDRA Life Sciences

ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ENDRA Life Sciences reports Q1 loss, eyes market expansion

ENDRA Life Sciences is navigating challenges in a competitive market while leveraging its strengths in innovation and strategic partnerships. The company's performance in Q1 2024 reflects progress in clinical research and regulatory alignment for its TAEUS system.

ENDRA Life Sciences charts strategic course for growth and innovation

ENDRA Life Sciences is making strategic changes to drive future growth and innovation. With a focus on regulatory alignment, clinical trials, and business strategy refinement, the company aims to enhance its market position. Despite financial challenges, ENDRA remains optimistic about its future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster titled “Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity” for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego. “This presentation highlights the potential of our.

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled “Method and System for Monitoring Tissue Temperature.” The ‘282 patent relates to a novel method and system for monitoring tissue ablation during minimally invasive thermal surgical interventions by utilizing ENDRA's TAEUS® system. It is related to ENDRA.

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one of the leading medical research centers in Europe. LMU University Hospital is conducting a post market clinical study to collect data to assess TAEUS' liver fat measurement capabilities against the gold standard.

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Data I/O

The Dow Jones index closed higher by more than 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

Data I/O And 2 Other Stocks Under $5 Executives Are Buying

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To regain compliance.

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2024 Earnings Conference Call August 22, 2024 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Alexander Tokman - Acting CEO Ziad Rouag - Head of Regulatory and Clinical Affairs Michael Thornton - Chief Technology Officer Richard Jacroux - CFO Conference Call Participants Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.

ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update: New executive team Subsequent to quarter-end, ENDRA announced leadership changes. Board member Alexander Tokman was appointed as acting CEO, bringing 24+ years of global commercial leadership experien.

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on August 20, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, August 20, 2024, and will continue to tra.

ENDRA Life Sciences Announces Reverse Stock Split

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as reg.

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its Board of Directors has appointed Alexander Tokman as acting Chief Executive Officer to replace Francois Michelon, who stepped down from his role as Chief Executive Officer and as a member of the Board of Directors to pursue other endeavors. The Company also announced the addition to its senior management team of Ziad Rouag as Head o.

ENDRA Life Sciences Announces Leadership Changes

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate develop.

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

ENDRA Life Sciences (NASDAQ: NDRA ) stock is up on Monday after the clinical diagnostic ultrasound technology company revealed an investment from S.H.N. Financial Investments Ltd.

Why Is ENDRA Life Sciences (NDRA) Stock Up 36% Today?

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. The offering is.

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best will host a complimentary webinar titled “The Case for Engaging Defense Counsel Pre-Lawsuit,” on June 25, 2024, at 2:00 p.m. ET. In this webinar, sponsored by Three Griffins, Inc., a panel of insurance claims experts will examine the path from claim to lawsuit, and best practices on minimizing loss through appropriate legal consultation. Register now. Panelists include: Daniel Herbert, president/CEO, Three Griffins, Inc. Donald J. Richardson, shareholder,.

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing. Prior to the meeting, ENDRA provided the FDA with a detailed description of the TAEUS technology to be used in cl.

ENDRA Provides Update Following In-person Meeting with FDA

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences First Quarter 2024 Financial Results Conference call. All participants will be in a listen-only mode.

ENDRA Life Sciences Inc. (NDRA) Q1 2024 Earnings Call Transcript

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business update. Highlights from the first quarter of 2024 and recent weeks include: Installed the first TAEUS system in the UK at King's College Hospital for clinical evaluation. King's College Hospital NHS Foundation Trust (KCH) in London is one of the leading centers of.

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and an.

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of five new patents, including three in Europe and two in China. ENDRA's intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the TAEUS system with its novel thermoacoustic technology. "With the issuance of these five patents, we've reached a significant milestone of 80 global patents," sa.

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

ENDRA Life Sciences Inc. (NDRA) Q4 2023 Earnings Call Transcript

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update. Highlights from the fourth quarter of 2023 and recent weeks include: Installed first TAEUS system in the UK at King's College Hospital for clinical evaluation. King's College Hospital NHS Foundation Trust (KCH) in London is one of the leading cen.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate deve.

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that it has installed a TAEUS liver system at King's College Hospital NHS Foundation Trust (KCH) in London, one of the leading centers of excellence in the United Kingdom's National Health Service (NHS). KCH will use ENDRA's TAEUS liver system in a clinical study to compare its liver fat assessment accuracy with MRI, the acknowledged research standard.

ENDRA Life Sciences Installs First TAEUS System in the UK

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), welcomes the adoption of the ICD-10 K76.0 code for the diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD). This pivotal update supports recent important advancements in the field of liver disease to underscore the increasing recognition of NAFLD's impact on global health by insurers and healthcare providers alike. ENDRA's TAEUS system has received a CE mark.

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe. ENDRA's intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS system with its novel thermoacoustic technology. These patents protect novel innovations integral to the TAEUS system, ensuring maximum radiofre.

News for ENDRA Life Sciences Stock (NDRA)